drugset
drugset / Trial / NCT04148209

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

NCT04148209 ↗

Phase 1 Completed 22 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of PF-07081532 in healthy adult participants.

Timeline

Start
2019-11-05
Primary completion
2020-03-17
Completion
2020-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject lotiglipron Small molecule — Oral

Indications

No indication recorded.